181 related articles for article (PubMed ID: 22399213)
1. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
3. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
[TBL] [Abstract][Full Text] [Related]
4. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
5. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
6. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
7. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
[TBL] [Abstract][Full Text] [Related]
9. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
[TBL] [Abstract][Full Text] [Related]
11. 17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days.
Mason MV; House KM; Fuest CM; Fitzgerald DR; Kitson BJ; Inglis JA
Manag Care; 2005 Oct; 14(10):58-63. PubMed ID: 16277194
[TBL] [Abstract][Full Text] [Related]
12. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
13. Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
Cross-Barnet C; Benatar S; Courtot B; Hill I; Johnston E; Cheeks M
Matern Child Health J; 2018 Nov; 22(11):1607-1616. PubMed ID: 29956128
[TBL] [Abstract][Full Text] [Related]
14. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
15. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
[TBL] [Abstract][Full Text] [Related]
16. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
[TBL] [Abstract][Full Text] [Related]
17. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
Timofeev J; Feghali M; Boyle A; Istwan N; Rhea D; Driggers RW
J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB
Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
[TBL] [Abstract][Full Text] [Related]
19. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
Barton JR; Barton LA; Istwan NB; Rhea DJ; Desch CN; Sibai BM
Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the use of 17P in pregnant managed Medicaid members.
Mason MV; House KM; Linehan J; Speers CA; Joseph LM; Littlejohn R
Manag Care; 2008 Jan; 17(1):47-52. PubMed ID: 18274315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]